{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:34:20Z","timestamp":1791815660069,"version":"4.3.4"},"reference-count":255,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["JBR 103838"],"award-info":[{"award-number":["JBR 103838"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"DOI":"10.1093\/brain\/awx327","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T15:11:39Z","timestamp":1511536299000},"page":"1263-1285","source":"Crossref","is-referenced-by-count":204,"title":["Neurotransmitter deficits from frontotemporal lobar degeneration"],"prefix":"10.1093","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-0670","authenticated-orcid":false,"given":"Alexander G","family":"Murley","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Herchel Smith Building, Robinson Way, Cambridge, CB2 0SZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Herchel Smith Building, Robinson Way, Cambridge, CB2 0SZ, UK"},{"name":"MRC Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, Cambridge, CB2 7EF, UK"},{"name":"Behavioural and Clinical Neurosciences Institute, University of Cambridge, Sir William Hardy Building, Downing Street, Cambridge, CB2 3EB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"key\n\t\t\t\t20180625113834_awx327-B1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3174\/ajnr.A2587","article-title":"Proton MR spectroscopy\u2014detectable major neurotransmitters of the brain: biology and possible clinical applications","volume":"33","author":"Agarwal","year":"2012","journal-title":"AJNR Am J Neuroradiol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10038-008-0344-5","article-title":"Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy","volume":"53","author":"Albani","year":"2008","journal-title":"J Hum Genet"},{"key":"key\n\t\t\t\t20180625113834_awx327-B3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/jnnp-2013-307035","article-title":"Validation of the new consensus criteria for the diagnosis of corticobasal degeneration","volume":"85","author":"Alexander","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B4","doi-asserted-by":"crossref","first-page":"e1000489","DOI":"10.1371\/journal.pbio.1000489","article-title":"Broca\u2019s region: novel organizational principles and multiple receptor mapping","volume":"8","author":"Amunts","year":"2010","journal-title":"PLoS Biol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17482960601073543","article-title":"Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline","volume":"8","author":"Anneser","year":"2007","journal-title":"Amyotroph Lateral Scler"},{"key":"key\n\t\t\t\t20180625113834_awx327-B6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s007020200041","article-title":"Steele-Richardson-Olszewski-syndrome: the relation of dopamine D2 receptor binding and subcortical lesions in MRI","volume":"109","author":"Arnold","year":"2002","journal-title":"J Neural Transm"},{"key":"key\n\t\t\t\t20180625113834_awx327-B8","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1002\/cne.23430","article-title":"Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases","volume":"521","author":"Arnold","year":"2013","journal-title":"J Comp Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2012.09.006","article-title":"Serotonin receptors involved in antidepressant effects","volume":"137","author":"Artigas","year":"2013","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t20180625113834_awx327-B10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/jnnp.65.2.155","article-title":"Brain muscarinic receptors in progressive supranuclear palsy and Parkinson\u2019s disease: a positron emission tomographic study","volume":"65","author":"Asahina","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.neuro.28.061604.135709","article-title":"An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance","volume":"28","author":"Aston-Jones","year":"2005","journal-title":"Annu Rev Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.brainres.2016.03.001","article-title":"Locus coeruleus: from global projection system to adaptive regulation of behavior","volume":"1645","author":"Aston-Jones","year":"2016","journal-title":"Brain Res"},{"key":"key\n\t\t\t\t20180625113834_awx327-B13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrneurol.2016.14","article-title":"Parkinsonism, movement disorders and genetics in frontotemporal dementia","volume":"12","author":"Baizabal-Carvallo","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B14","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature05016","article-title":"Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17","volume":"442","author":"Baker","year":"2006","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180625113834_awx327-B15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5_HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/jcbfm.1986.26","article-title":"Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy","volume":"6","author":"Baron","year":"1986","journal-title":"J Cereb Blood Flow Metab"},{"key":"key\n\t\t\t\t20180625113834_awx327-B17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrn2044","article-title":"Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks","volume":"8","author":"Bartos","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.neuron.2012.10.038","article-title":"Canonical microcircuits for predictive coding","volume":"76","author":"Bastos","year":"2012","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20180625113834_awx327-B19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol Rev"},{"key":"key\n\t\t\t\t20180625113834_awx327-B20","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1212\/WNL.0b013e3182886a76","article-title":"Pedunculopontine nucleus: functional organization and clinical implications","volume":"80","author":"Benarroch","year":"2013","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/brain\/awn012","article-title":"Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study","volume":"131","author":"Le Ber","year":"2008","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/brain\/aws004","article-title":"Characterization of frontotemporal dementia and\/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72","volume":"135","author":"Boeve","year":"2012","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.53.4.795","article-title":"Pathologic heterogeneity in clinically diagnosed corticobasal degeneration","volume":"53","author":"Boeve","year":"1999","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neurobiolaging.2008.04.004","article-title":"Establishing short-term prognosis in frontotemporal lobar degeneration spectrum: role of genetic background and clinical phenotype","volume":"31","author":"Borroni","year":"2010","journal-title":"Neurobiol Aging"},{"key":"key\n\t\t\t\t20180625113834_awx327-B25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-007-0992-8","article-title":"Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy","volume":"196","author":"Bowen","year":"2008","journal-title":"Psychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B26","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/WAD.0b013e31815c345e","article-title":"Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies","volume":"21","author":"Boxer","year":"2007","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","article-title":"Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Boxer","year":"2013","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ana.410310209","article-title":"Striatal D2 receptor status in patients with Parkinson\u2019s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography","volume":"31","author":"Brooks","year":"1992","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5414\/NPP30104","article-title":"Differential degeneration of the locus coeruleus in dementia subtypes","volume":"30","author":"Brunnstr\u00f6m","year":"2011","journal-title":"Clin Neuropathol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-neuro-062111-150444","article-title":"Mechanisms of gamma oscillations","volume":"4","author":"Buzs\u00e1ki","year":"2012","journal-title":"Annu Rev Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B31","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/npp.2012.142","article-title":"The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T 1H-MRS study","volume":"37","author":"Cai","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/nn1964","article-title":"Long story short: the serotonin transporter in emotion regulation and social cognition","volume":"10","author":"Canli","year":"2007","journal-title":"Nat Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/mp.2011.31","article-title":"A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior","volume":"17","author":"Carl\u00e9","year":"2011","journal-title":"Mol Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0006-8993(97)01566-7","article-title":"5-HT 1B receptor binding in degenerative movement disorders","volume":"790","author":"Castro","year":"1998","journal-title":"Brain Res"},{"key":"key\n\t\t\t\t20180625113834_awx327-B35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Front Integr Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B36","doi-asserted-by":"crossref","first-page":"e2.59","DOI":"10.1136\/jnnp-2013-306573.151","article-title":"Dopamine Transporter (DAT) imaging can be normal with neuropathologically confirmed Cortiobasal Degeneration","volume":"84","author":"Chaal","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B37","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1073\/pnas.1320827111","article-title":"Heterogeneous organization of the locus coeruleus projections to prefrontal and motor cortices","volume":"111","author":"Chandler","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180625113834_awx327-B38","doi-asserted-by":"crossref","first-page":"107064","DOI":"10.1155\/2014\/107064","article-title":"Trial of zolpidem, eszopiclone, and other GABA agonists in a patient with progressive supranuclear palsy","volume":"2014","author":"Chang","year":"2014","journal-title":"Case Rep Med"},{"key":"key\n\t\t\t\t20180625113834_awx327-B39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.31887\/DCNS.2010.12.4\/ycharnay","article-title":"Brain serotonergic circuitries","volume":"12","author":"Charnay","year":"2010","journal-title":"Dialogues Clin Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0306-4522(93)90240-G","article-title":"Serotoninergic terminal transporters are differentially affected in Parkinson\u2019s disease and progressive supranuclear palsy: an autoradiographic study with [3H] citalopram","volume":"54","author":"Chinaclia","year":"1993","journal-title":"Neuroscience"},{"key":"key\n\t\t\t\t20180625113834_awx327-B41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/153331750201700504","article-title":"Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration","volume":"17","author":"Chow","year":"2002","journal-title":"Am J Alzheimer\u2019s Dis Other Dementias"},{"key":"key\n\t\t\t\t20180625113834_awx327-B42","doi-asserted-by":"crossref","first-page":"e18301","DOI":"10.1371\/journal.pone.0018301","article-title":"Dopamine transporter spect imaging in corticobasal syndrome","volume":"6","author":"Cilia","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180625113834_awx327-B43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/157015906776359540","article-title":"Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology","volume":"4","author":"Ciranna","year":"2006","journal-title":"Curr Neuropharmacol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2005.03.024","article-title":"Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson\u2019s disease","volume":"30","author":"Cools","year":"2006","journal-title":"Neurosci Biobehav Rev"},{"key":"key\n\t\t\t\t20180625113834_awx327-B45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jocn.2009.05.038","article-title":"The use of zolpidem in the treatment of progressive supranuclear palsy","volume":"17","author":"Cotter","year":"2010","journal-title":"J Clin Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02246578","article-title":"The \u03b12 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type","volume":"123","author":"Coull","year":"1996","journal-title":"Psychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B47","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","article-title":"Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes","volume":"86","author":"Coyle-Gilchrist","year":"2016","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/cercor\/bhs296","article-title":"Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys","volume":"24","author":"Cubillo","year":"2014","journal-title":"Cereb Cortex"},{"key":"key\n\t\t\t\t20180625113834_awx327-B49","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.jnen.0000171649.86718.f2","article-title":"Abnormal group I metabotropic glutamate receptor expression and signaling in the frontal cortex in Pick disease","volume":"64","author":"Dalfo","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B50","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.neuron.2011.01.020","article-title":"Impulsivity, compulsivity, and top-down cognitive control","volume":"69","author":"Dalley","year":"2011","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20180625113834_awx327-B51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJM199908123410721","article-title":"Zolpidem in progressive supranuclear palsy","volume":"341","author":"Daniele","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180625113834_awx327-B52","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1476-5381.2012.02057.x","article-title":"Alzheimer\u2019s disease, \u03b2-amyloid, glutamate, NMDA receptors and memantine\u2014searching for the connections","volume":"167","author":"Danysz","year":"2012","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF03033787","article-title":"Neuroprotective and symptomatological action of memantine relevant for Alzheimer\u2019s disease\u2013a unified glutamatergic hypothesis on the mechanism of action","volume":"2","author":"Danysz","year":"2000","journal-title":"Neurotox Res"},{"key":"key\n\t\t\t\t20180625113834_awx327-B54","first-page":"250865","article-title":"Zolpidem in progressive supranuclear palsy","volume":"2013","author":"Dash","year":"2013","journal-title":"Case Rep Neurol Med"},{"key":"key\n\t\t\t\t20180625113834_awx327-B55","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0893-133X(01)00265-2","article-title":"The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus","volume":"25","author":"Dawson","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B56","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","article-title":"Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial","volume":"172","author":"Deakin","year":"2004","journal-title":"Psychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B57","doi-asserted-by":"crossref","first-page":"552","DOI":"10.15252\/embr.201541439","article-title":"The Tau\/A152T mutation, a risk factor for frontotemporal spectrum disorders, leads to NR2B receptor mediated excitotoxicity","volume":"17","author":"Decker","year":"2016","journal-title":"EMBO Rep"},{"key":"key\n\t\t\t\t20180625113834_awx327-B58","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneurol.2014.78","article-title":"The role of FUS gene variants in neurodegenerative diseases","volume":"10","author":"Deng","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B59","doi-asserted-by":"crossref","first-page":"II6","DOI":"10.1007\/BF03161076","article-title":"Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration","volume":"246 (Suppl 2)","author":"Dickson","year":"1999","journal-title":"J Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B60","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","article-title":"Neuropathology of variants of progressive supranuclear palsy","volume":"23","author":"Dickson","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B61","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.neuint.2007.10.018","article-title":"The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia","volume":"52","author":"Engelborghs","year":"2008","journal-title":"Neurochem Int"},{"key":"key\n\t\t\t\t20180625113834_awx327-B62","first-page":"1080","article-title":"Evidence for an association between the CSF HVA:5-HIAA ratio and aggressiveness in frontotemporal dementia but not in Alzheimer\u2019s disease","volume":"75","author":"Engelborghs","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B63","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1148\/radiology.203.3.9169712","article-title":"Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy","volume":"203","author":"Ernst","year":"1997","journal-title":"Radiology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B64","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.psych.48.1.649","article-title":"Central cholinergic systems and cognition","volume":"48","author":"Everitt","year":"1997","journal-title":"Annu Rev Psychol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000051214","article-title":"Neurons and their dendrites in frontotemporal dementia","volume":"10","author":"Ferrer","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B66","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0269881113495118","article-title":"The size, burden and cost of disorders of the brain in the UK","volume":"27","author":"Fineberg","year":"2013","journal-title":"J Psychopharmacol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B67","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1007\/s00213-015-3938-6","article-title":"Application of cross-species PET imaging to assess neurotransmitter release in brain","volume":"232","author":"Finnema","year":"2015","journal-title":"Psychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B68","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.54.9.1768","article-title":"PET measures of benzodiazepine receptors in progressive supranuclear palsy","volume":"54","author":"Foster","year":"2000","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B69","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.410410606","article-title":"Frontotemporal dementia and parkinsonism linked to chromosome 17","volume":"41","author":"Foster","year":"1997","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ana.20365","article-title":"Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration","volume":"57","author":"Franceschi","year":"2005","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B71","first-page":"172","article-title":"Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy","volume":"4","author":"Francis","year":"1993","journal-title":"Dementia"},{"key":"key\n\t\t\t\t20180625113834_awx327-B72","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer\u2019 s disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B73","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/npp.2008.104","article-title":"Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects","volume":"34","author":"Frankle","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B74","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1146\/annurev.neuro.051508.135603","article-title":"Neuronal gamma-band synchronization as a fundamental process in cortical computation","volume":"32","author":"Fries","year":"2009","journal-title":"Annu Rev Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B75","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1600-0404.1994.tb01661.x","article-title":"Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer\u2019s disease and dementia of frontal type: preliminary results","volume":"89","author":"Frisoni","year":"1994","journal-title":"Acta Neurol Scand"},{"key":"key\n\t\t\t\t20180625113834_awx327-B76","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.neuroimage.2010.12.077","article-title":"Relating MEG measured motor cortical oscillations to resting \u03b3- aminobutyric acid (GABA) concentration","volume":"15","author":"Gaetz","year":"2011","journal-title":"Neuroimage"},{"key":"key\n\t\t\t\t20180625113834_awx327-B77","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hbm.21339","article-title":"Functional and structural correlates of the aging brain: relating visual cortex (V1) gamma band responses to age-related structural change","volume":"33","author":"Gaetz","year":"2012","journal-title":"Hum Brain Mapp"},{"key":"key\n\t\t\t\t20180625113834_awx327-B78","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/brain\/awn047","article-title":"Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer\u2019s disease","volume":"131","author":"Garbutt","year":"2008","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B79","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/nm.3717","article-title":"Alterations in microRNA-124 and AMPA receptors contribute to social behavioral deficits in frontotemporal dementia","volume":"20","author":"Gascon","year":"2014","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20180625113834_awx327-B80","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1212\/WNL.41.7.986","article-title":"Idazoxan treatment in progressive supranuclear palsy","volume":"41","author":"Ghika","year":"1991","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B81","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/brain\/112.5.1171","article-title":"Corticobasal degeneration","volume":"112","author":"Gibb","year":"1989","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuroimage.2015.08.057","article-title":"Profiling neuronal ion channelopathies with non-invasive brain imaging and dynamic causal models: case studies of single gene mutations","volume":"124","author":"Gilbert","year":"2016","journal-title":"Neuroimage"},{"key":"key\n\t\t\t\t20180625113834_awx327-B83","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.0b013e3181dc1a55","article-title":"Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes","volume":"74","author":"Gilman","year":"2010","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B84","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.neuropharm.2011.03.015","article-title":"NMDA receptors, cognition and schizophrenia\u2014testing the validity of the NMDA receptor hypofunction hypothesis","volume":"62","author":"Gilmour","year":"2012","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B85","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/ene.12196","article-title":"Decreased striatal dopamine transporter uptake in the non-fluent\/agrammatic variant of primary progressive aphasia","volume":"20","author":"Gil-Navarro","year":"2013","journal-title":"Eur J Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B86","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/155005940403500212","article-title":"Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study","volume":"35","author":"Goforth","year":"2004","journal-title":"Clin EEG Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B87","doi-asserted-by":"crossref","first-page":"723184","DOI":"10.1155\/2011\/723184","article-title":"GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia","volume":"2011","author":"Gonzalez-Burgos","year":"2011","journal-title":"Neural Plast"},{"key":"key\n\t\t\t\t20180625113834_awx327-B88","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/cercor\/bhr107","article-title":"The glutamatergic component of the mesocortical pathway emanating from different subregions of the ventral midbrain","volume":"22","author":"Gorelova","year":"2012","journal-title":"Cereb Cortex"},{"key":"key\n\t\t\t\t20180625113834_awx327-B89","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"2","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B90","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/brain\/awx074","article-title":"Repurposed drugs targeting eIF2\u03b1-P-mediated translational repression prevent neurodegeneration in mice","author":"Halliday","year":"2017","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B91","first-page":"507","article-title":"Neocortical morphometry and cholinergic neurochemistry in Pick\u2019s disease","volume":"131","author":"Hansen","year":"1988","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B92","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/exnr.1997.6415","article-title":"Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata","volume":"144","author":"Hardman","year":"1997","journal-title":"Exp Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B93","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/lm.60803","article-title":"Role of the serotonin 5-HT2A receptor in learning","volume":"10","author":"Harvey","year":"2003","journal-title":"Learn Mem"},{"key":"key\n\t\t\t\t20180625113834_awx327-B94","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.44.11.2015","article-title":"Preliminary NINDS neuropathologic criteria for Steele- Richardson-Olszewski syndrome (progressive supranuclear palsy)","volume":"44","author":"Hauw","year":"1994","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B95","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/mds.25123","article-title":"Clinicopathological study in progressive supranuclear palsy with pedunculopontine stimulation","volume":"27","author":"Hazrati","year":"2012","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B96","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/brain\/123.7.1410","article-title":"Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson\u2019s disease: clinical and therapeutic implications","volume":"123 (Pt 7)","author":"Henderson","year":"2000","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B97","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","article-title":"Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia","volume":"20","author":"Herrmann","year":"2012","journal-title":"Am J Geriatr Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B98","doi-asserted-by":"crossref","first-page":"16628","DOI":"10.1073\/pnas.1308706110","article-title":"Disrupting the clustering of GABAA receptor \u03b12 subunits in the frontal cortex leads to reduced \u03b3-power and cognitive deficits","volume":"110","author":"Hines","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180625113834_awx327-B99","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/awq120","article-title":"Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia","volume":"133","author":"Hirano","year":"2010","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B100","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1073\/pnas.84.16.5976","article-title":"Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy","volume":"84","author":"Hirsch","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180625113834_awx327-B101","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy\u2014the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B102","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0006-8993(91)91747-O","article-title":"[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson\u2019s disease and progressive supranuclear palsy","volume":"565","author":"Holemans","year":"1991","journal-title":"Brain Res"},{"key":"key\n\t\t\t\t20180625113834_awx327-B103","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jchemneu.2003.10.002","article-title":"The human raphe nuclei and the serotonergic system","volume":"26","author":"Hornung","year":"2003","journal-title":"J Chem Neuroanat"},{"key":"key\n\t\t\t\t20180625113834_awx327-B104","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-7091-6641-3_17","article-title":"Brain monoamines in progressive supranuclear palsy\u2013comparison with idiopathic Parkinson\u2019s disease","volume":"42","author":"Hornykiewicz","year":"1994","journal-title":"J Neural Transm Suppl"},{"key":"key\n\t\t\t\t20180625113834_awx327-B105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.wnl.0000191304.55196.4d","article-title":"A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia","volume":"66","author":"Huey","year":"2006","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B106","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.nicl.2013.03.009","article-title":"Reorganisation of brain networks in frontotemporal dementia and progressive supranuclear palsy","volume":"2","author":"Hughes","year":"2013","journal-title":"Neuroimage Clin"},{"key":"key\n\t\t\t\t20180625113834_awx327-B107","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/brain\/awv133","article-title":"Improving response inhibition systems in frontotemporal dementia with citalopram","volume":"138","author":"Hughes","year":"2015","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B108","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5\u2019-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180625113834_awx327-B109","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2006.01.006","article-title":"Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson\u2019s disease: analysis with [(123)I]IPT single photon emission computed tomography","volume":"244","author":"Im","year":"2006","journal-title":"J Neurol Sci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.pnpbp.2004.05.026","article-title":"Role of presynaptic a2-adrenoceptors in antidepressant action: recent findings from microdialysis studies","volume":"28","author":"Invernizzi","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B111","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ana.24559","article-title":"Deep clinical and neuropathological phenotyping of Pick disease","volume":"79","author":"Irwin","year":"2016","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B112","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-7091-6641-3_16","article-title":"Cholinergic and peptidergic systems in PSP","volume":"42","author":"Javoy-Agid","year":"1994","journal-title":"J Neural Transm Suppl"},{"key":"key\n\t\t\t\t20180625113834_awx327-B113","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jnnp.51.4.540","article-title":"The pedunculopontine nucleus in Parkinson\u2019s disease, progressive supranuclear palsy and Alzheimer\u2019s disease","volume":"51","author":"Jellinger","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B114","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/WAD.0b013e3181cf468d","article-title":"Pilot trial of memantine in primary progressive aphasia","volume":"24","author":"Johnson","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1212\/WNL.41.1.25","article-title":"Mesencephalic cholinergic nuclei in progressive supranuclear palsy","volume":"41","author":"Juncos","year":"1991","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B116","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00415-013-6886-2","article-title":"Normal dopamine transporter SPECT in neuropathologically confirmed corticobasal degeneration","volume":"260","author":"Kaasinen","year":"2013","journal-title":"J Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B117","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1474-4422(08)70165-0","article-title":"NMDA receptors in clinical neurology: excitatory times ahead","volume":"7","author":"Kalia","year":"2008","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B118","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0022-510X(88)90020-2","article-title":"Studies on neurotransmitter markers of the basal ganglia in Pick\u2019s disease, with special reference to dopamine reduction","volume":"83","author":"Kanazawa","year":"1988","journal-title":"J Neurol Sci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B119","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00401-002-0621-x","article-title":"Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration","volume":"105","author":"Kasashima","year":"2003","journal-title":"Acta Neuropathol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B120","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/brain\/awu117","article-title":"Targeting impulsivity in Parkinson\u2019s disease using atomoxetine","volume":"137","author":"Kehagia","year":"2014","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B121","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s12031-011-9616-1","article-title":"Extrapyramidal syndromes in frontotemporal degeneration","volume":"45","author":"Kertesz","year":"2011","journal-title":"J Mol Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B122","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","article-title":"Galantamine in frontotemporal dementia and primary progressive aphasia","volume":"25","author":"Kertesz","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B123","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10042","article-title":"Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP","volume":"17","author":"Kim","year":"2002","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B124","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.21004","article-title":"Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration","volume":"21","author":"Klaffke","year":"2006","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B125","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archneur.55.8.1099","article-title":"Pharmacological therapy in progressive supranuclear palsy","volume":"55","author":"Kompoliti","year":"1998","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.parkreldis.2006.05.018","article-title":"Drug intervention for freezing of gait resistant to dopaminergic therapy: a pilot study","volume":"12","author":"Kondo","year":"2006","journal-title":"Park Relat Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B127","doi-asserted-by":"crossref","first-page":"16347","DOI":"10.1038\/srep16347","article-title":"Gamma oscillations in V1 are correlated with GABAA receptor density: a multi-modal MEG and Flumazenil-PET study","volume":"5","author":"Kujala","year":"2015","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t20180625113834_awx327-B128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pscychresns.2007.07.003","article-title":"Serotonin-1A receptors in frontotemporal dementia compared with controls","volume":"156","author":"Lanct\u00f4t","year":"2007","journal-title":"Psychiatry Res Neuroimaging"},{"key":"key\n\t\t\t\t20180625113834_awx327-B129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-3-7091-6641-3_18","article-title":"Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy","volume":"42","author":"Landwehrmeyer","year":"1994","journal-title":"J Neural Transm Suppl"},{"key":"key\n\t\t\t\t20180625113834_awx327-B130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0149-7634(96)00043-7","article-title":"Dopamine\/glutamate interactions in Parkinson\u2019s disease","volume":"21","author":"Lange","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"key":"key\n\t\t\t\t20180625113834_awx327-B131","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/brain\/awx101","article-title":"Apathy and impulsivity in frontotemporal lobar degeneration syndromes","volume":"140","author":"Lansdall","year":"2017","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B132","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s004150050534","article-title":"Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration","volume":"246","author":"Laureys","year":"1999","journal-title":"J Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B133","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","article-title":"Frontotemporal dementia: a randomised, controlled trial with trazodone","volume":"17","author":"Lebert","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B134","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00429-014-0978-3","article-title":"In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD","volume":"221","author":"Leuzy","year":"2016","journal-title":"Brain Struct Funct"},{"key":"key\n\t\t\t\t20180625113834_awx327-B135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.45.1.127","article-title":"Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA","volume":"45","author":"Levy","year":"1995","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B136","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jalz.2009.04.1231","article-title":"Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis","volume":"6","author":"Liepelt","year":"2010","journal-title":"Alzheimers Dement"},{"key":"key\n\t\t\t\t20180625113834_awx327-B137","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ana.410360112","article-title":"Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy","volume":"36","author":"Litvan","year":"1994","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B138","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00005072-199601000-00010","article-title":"Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders","volume":"55","author":"Litvan","year":"1996","journal-title":"J Neuropathol Exp Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B139","first-page":"467","article-title":"Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy","volume":"57","author":"Litvan","year":"2001"},{"key":"key\n\t\t\t\t20180625113834_awx327-B140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","article-title":"Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update","volume":"119","author":"MacKenzie","year":"2010","journal-title":"Acta Neuropathol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B141","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/npp.2012.264","article-title":"Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition","volume":"38","author":"Macoveanu","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B142","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0893-133X(95)00137-3","article-title":"NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers","volume":"14","author":"Malhotra","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B143","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.tins.2007.05.003","article-title":"Role of GABAergic inhibition in hippocampal network oscillations","volume":"30","author":"Mann","year":"2007","journal-title":"Trends Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B144","first-page":"1813","article-title":"Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging","volume":"22","author":"Mark","year":"2001","journal-title":"Am J Neuroradiol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.22307","article-title":"Atomoxetine for the treatment of executive dysfunction in Parkinson\u2019s disease: a pilot open-label study","volume":"24","author":"Marsh","year":"2009","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B146","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1148\/radiol.12112650","article-title":"Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol","volume":"265","author":"Mazere","year":"2012","journal-title":"Radiology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B147","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuroscience.2008.01.064","article-title":"Noradrenergic, but not cholinergic, deafferentation of prefrontal cortex impairs attentional set-shifting","volume":"153","author":"McGaughy","year":"2008","journal-title":"Neuroscience"},{"key":"key\n\t\t\t\t20180625113834_awx327-B148","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0167-4943(84)90007-4","article-title":"Neurochemical enzyme changes in Alzheimer\u2019s and Pick\u2019s disease","volume":"3","author":"Meier-Ruge","year":"1984","journal-title":"Arch Gerontol Geriatr"},{"key":"key\n\t\t\t\t20180625113834_awx327-B149","doi-asserted-by":"crossref","first-page":"1007S","DOI":"10.1093\/jn\/130.4.1007S","article-title":"Glutamate as a neurotransmitter in the brain: review of physiology and pathology","volume":"130","author":"Meldrum","year":"2000","journal-title":"J Nutr"},{"key":"key\n\t\t\t\t20180625113834_awx327-B150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","article-title":"Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia","volume":"15","author":"Mendez","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B151","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/WNN.0b013e318223f6c6","article-title":"Anti-saccade performance predicts executive function and brain structure in normal elders","volume":"24","author":"Mirsky","year":"2011","journal-title":"Cogn Behav Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B152","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/136515002753489416","article-title":"Fluvoxamine for the treatment of depression and parkinsonism in progressive supranuclear palsy","volume":"6","author":"Miyaoka","year":"2002","journal-title":"Int J Psychiatry Clin Pract"},{"key":"key\n\t\t\t\t20180625113834_awx327-B153","doi-asserted-by":"crossref","first-page":"8227","DOI":"10.1523\/JNEUROSCI.4255-12.2013","article-title":"Free energy, precision and learning: the role of cholinergic neuromodulation Europe PMC Funders Group","volume":"33","author":"Moran","year":"2013","journal-title":"J Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B154","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.cub.2011.06.053","article-title":"An in vivo assay of synaptic function mediating human cognition","volume":"21","author":"Moran","year":"2011","journal-title":"Curr Biol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B155","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00002512-200421140-00003","article-title":"Rivastigmine in frontotemporal dementia","volume":"21","author":"Moretti","year":"2004","journal-title":"Drugs Aging"},{"key":"key\n\t\t\t\t20180625113834_awx327-B156","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000067021","article-title":"Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms: a randomized, controlled, open 14-month study","volume":"49","author":"Moretti","year":"2003","journal-title":"Eur Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B157","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/153331750301800410","article-title":"Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer\u2019s disease and other dementias: a 24-month follow-up of 68 patients","volume":"18","author":"Moretti","year":"2003","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"key\n\t\t\t\t20180625113834_awx327-B158","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00401-002-0555-3","article-title":"Lewy bodies in progressive supranuclear palsy","volume":"104","author":"Mori","year":"2002","journal-title":"Acta Neuropathol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B159","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/319774a0","article-title":"Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5","volume":"319","author":"Morris","year":"1986","journal-title":"Nature"},{"key":"key\n\t\t\t\t20180625113834_awx327-B160","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/mds.21907","article-title":"Excessive dopamine neuron loss in progressive supranuclear palsy","volume":"23","author":"Murphy","year":"2008","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B161","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0269881114536790","article-title":"The use of magnetoencephalography in the study of psychopharmacology (pharmaco-MEG)","volume":"28","author":"Muthukumaraswamy","year":"2014","journal-title":"J Psychopharmacol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B162","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1073\/pnas.0900728106","article-title":"Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans","volume":"106","author":"Muthukumaraswamy","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180625113834_awx327-B163","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/npp.2013.9","article-title":"Elevating endogenous GABA levels with GAT-1 blockade modulates evoked but not induced responses in human visual cortex","volume":"38","author":"Muthukumaraswamy","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B164","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0278-5846(95)00264-2","article-title":"A juvenile case of frontotemporal dementia: neurochemical and neuropathological investigations","volume":"19","author":"Nagaoka","year":"1995","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B165","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0022-510X(96)00057-3","article-title":"PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration","volume":"139","author":"Nagasawa","year":"1996","journal-title":"J Neurol Sci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B166","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mds.26068","article-title":"Linking neuroscience with modern concepts of impulse control disorders in Parkinson\u2019s disease","volume":"30","author":"Napier","year":"2015","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B167","doi-asserted-by":"crossref","first-page":"219","DOI":"10.31887\/DCNS.2000.2.3\/jnewcomer","article-title":"NMDA receptor function, memory, and brain aging","volume":"2","author":"Newcomer","year":"2000","journal-title":"Dialogues Clin Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B168","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00213-008-1097-8","article-title":"Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex","volume":"200","author":"Newman","year":"2008","journal-title":"Psychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B169","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.25022","article-title":"C9ORF72 expansion in amyotrophic lateral sclerosis\/frontotemporal dementia also causes Parkinsonism","volume":"27","author":"O\u2019Dowd","year":"2012","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B170","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/jnnp.74.7.965","article-title":"Alterations of muscarinic acetylcholine receptors in atypical Pick\u2019s disease without Pick bodies","volume":"74","author":"Odawara","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B171","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2967\/jnumed.111.095224","article-title":"Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy","volume":"53","author":"Oh","year":"2012","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t20180625113834_awx327-B172","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev.med.55.091902.104422","article-title":"The scientific basis for the current treatment of Parkinson\u2019s disease","volume":"55","author":"Olanow","year":"2004","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20180625113834_awx327-B173","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrn919","article-title":"Is there more to GABA than synaptic inhibition?","volume":"3","author":"Owens","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B174","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1552-6569.2002.tb00139.x","article-title":"Comparison of striatal dopamine D2 receptors in Parkinson\u2019s disease and progressive supranuclear palsy patients using [I] iodobenzofuran single-photon emission computed tomography","volume":"12","author":"Oyanagi","year":"2002","journal-title":"J Neuroimaging"},{"key":"key\n\t\t\t\t20180625113834_awx327-B175","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jnen\/60.4.393","article-title":"Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features","volume":"60","author":"Oyanagi","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B176","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neulet.2007.05.049","article-title":"Extrapyramidal symptoms in frontotemporal dementia: prevalence and clinical correlations","volume":"422","author":"Padovani","year":"2007","journal-title":"Neurosci Lett"},{"key":"key\n\t\t\t\t20180625113834_awx327-B177","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1353-8020(00)00026-2","article-title":"Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene)","volume":"7","author":"Pal","year":"2001","journal-title":"Park Relat Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B178","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ana.410320516","article-title":"Dopamine D1 and D2 receptors in progressive supranuclear palsy: an autoradiographic study","volume":"32","author":"Pascual","year":"1992","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B179","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.nbd.2011.01.032","article-title":"Saccadic latency in Parkinson\u2019s disease correlates with executive function and brain atrophy, but not motor severity","volume":"43","author":"Perneczky","year":"2011","journal-title":"Neurobiol Dis"},{"key":"key\n\t\t\t\t20180625113834_awx327-B180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","article-title":"Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior","volume":"76","author":"Picciotto","year":"2012","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20180625113834_awx327-B181","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/brain\/awf069","article-title":"Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene","volume":"125","author":"Pickering-Brown","year":"2002","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B182","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0022-510X(88)90106-2","article-title":"D1 and D2-type dopamine receptors in patients with Parkinson\u2019s disease and progressive supranuclear palsy","volume":"86","author":"Pierot","year":"1988","journal-title":"J Neurol Sci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B183","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/gps.774","article-title":"Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration","volume":"18","author":"Pijnenburg","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B184","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.parkreldis.2012.10.010","article-title":"Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration","volume":"19","author":"Pirker","year":"2013","journal-title":"Park Relat Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B185","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3233\/JPD-150625","article-title":"Progressive dopamine transporter binding loss in autopsy-confirmed corticobasal degeneration","volume":"5","author":"Pirker","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"key\n\t\t\t\t20180625113834_awx327-B186","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euroneuro.2011.10.003","article-title":"Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy","volume":"22","author":"Porcelli","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B187","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1468-1331.2007.01687.x","article-title":"Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy","volume":"14","author":"Poujois","year":"2007","journal-title":"Eur J Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B188","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.neurobiolaging.2014.07.008","article-title":"Functional genetic variation in the serotonin 5-HTTLPR modulates brain damage in frontotemporal dementia","volume":"36","author":"Premi","year":"2015","journal-title":"Neurobiol Aging"},{"key":"key\n\t\t\t\t20180625113834_awx327-B189","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000051219","article-title":"Neurochemical features of frontotemporal dementia","volume":"10","author":"Procter","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B190","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/brain\/aww138","article-title":"Atomoxetine restores the response inhibition network in Parkinson\u2019s disease","volume":"139","author":"Rae","year":"2016","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B191","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.npp.1300886","article-title":"Methylphenidate (\u2019Ritalin\u2019) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia","volume":"31","author":"Rahman","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B192","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/jamaneurol.2016.2016","article-title":"Distinct subtypes of behavioral-variant frontotemporal dementia based on patterns of network degeneration HHS public access","volume":"73","author":"Ranasinghe","year":"2016","journal-title":"JAMA Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B193","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/mds.870130411","article-title":"Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy","volume":"13","author":"Rascol","year":"1998","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B194","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B195","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180625113834_awx327-B196","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/brain\/119.4.1137","article-title":"The nucleus raphe interpositus in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)","volume":"119 (Pt 4)","author":"Revesz","year":"1996","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B197","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199009063231013","article-title":"Brain GABA levels in asymptomatic Huntington\u2019s disease","volume":"323","author":"Reynolds","year":"1990","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180625113834_awx327-B198","first-page":"297","article-title":"Frontotemporal lobar degeneration: current perspectives","volume":"10","author":"Riedl","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"key\n\t\t\t\t20180625113834_awx327-B199","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/archpsyc.1978.01770280093010","article-title":"Are prophylactic antiparkinson drugs necessary? A Controlled Study of procyclidine withdrawal","volume":"35","author":"Rifkin","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B200","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1212\/WNL.58.10.1489","article-title":"Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia","volume":"58","author":"Rinne","year":"2002","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B201","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/nmt-2016-0027","article-title":"Managing cognition in progressive supranuclear palsy","volume":"6","author":"Rittman","year":"2016","journal-title":"Neurodegener Dis Manag"},{"key":"key\n\t\t\t\t20180625113834_awx327-B202","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.npp.1301487","article-title":"Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat","volume":"33","author":"Robinson","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B203","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with alzheimers-disease","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B204","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(14)70233-9","article-title":"C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis","volume":"14","author":"Rohrer","year":"2015","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1474-4422(14)70324-2","article-title":"Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the genetic frontotemporal dementia initiative (GENFI) study: a cross-sectional analysis","volume":"14","author":"Rohrer","year":"2015","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B206","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.22946","article-title":"Progressive supranuclear palsy syndrome presenting as progressive nonfluent aphasia: a neuropsychological and neuroimaging analysis","volume":"25","author":"Rohrer","year":"2010","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B207","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.neuron.2016.01.040","article-title":"DREADDs for neuroscientists","volume":"89","author":"Roth","year":"2016","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20180625113834_awx327-B208","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/med\/9780199655946.003.0007","article-title":"The basal ganglia in cognitive disorders","volume-title":"Oxford textbook of cognitive neurology and dementia","author":"Rowe","year":"2016"},{"key":"key\n\t\t\t\t20180625113834_awx327-B209","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/brain\/awn112","article-title":"Parkinson\u2019s disease and dopaminergic therapy\u2014differential effects on movement, reward and cognition","volume":"131","author":"Rowe","year":"2008","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B255","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/026988119601000303","article-title":"Systemic idazoxan impairs performance in a non-reversal shift test: implications for the role of the central noradrenergic systems in selective attention","volume":"10","author":"Rowe","year":"1996","journal-title":"J Psychopharmacol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B210","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.npp.1300642","article-title":"Selective cognitive impairments associated with NMDA receptor blockade in humans","volume":"30","author":"Rowland","year":"2005","journal-title":"Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B211","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ana.410180503","article-title":"Dopaminergic and cholinergic lesions in progressive supranuclear palsy","volume":"18","author":"Ruberg","year":"1985","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B212","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/jnnp.57.1.120","article-title":"Selective enhancement of executive function by idazoxan in a patient with dementia of the frontal lobe type","volume":"57","author":"Sahakian","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B213","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrn2573","article-title":"The locus coeruleus and noradrenergic modulation of cognition","volume":"10","author":"Sara","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B214","first-page":"205","article-title":"Magnetic resonance imaging and magnetic resonance spectroscopy in a patient with amyotrophic lateral sclerosis and frontotemporal dementia","volume":"32","author":"Sarac","year":"2008","journal-title":"Coll Antropol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/brain\/114.1.541","article-title":"Corticobasal degeneration\u2014a unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emmission tomography","volume":"114","author":"Sawle","year":"1991","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B216","doi-asserted-by":"crossref","first-page":"R1051","DOI":"10.1016\/j.cub.2015.09.039","article-title":"Organization of the locus coeruleus-norepinephrine system","volume":"25","author":"Schwarz","year":"2015","journal-title":"Curr Biol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B217","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000105159","article-title":"Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography","volume":"4","author":"Sedaghat","year":"2007","journal-title":"Neurodegener Dis"},{"key":"key\n\t\t\t\t20180625113834_awx327-B218","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp.2010.212225","article-title":"Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review","volume":"82","author":"Seelaar","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B219","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/brain\/121.12.2249","article-title":"Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain","volume":"121","author":"Selden","year":"1998","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B220","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/archneur.63.8.1154","article-title":"Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123i]\u03b2-cit spect analysis","volume":"63","author":"Seppi","year":"2006","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B221","doi-asserted-by":"crossref","first-page":"S416","DOI":"10.4103\/2152-7806.140208","article-title":"Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: report of three cases","volume":"5","author":"Servello","year":"2014","journal-title":"Surg Neurol Int"},{"key":"key\n\t\t\t\t20180625113834_awx327-B222","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/1531-8249(199907)46:1<62::AID-ANA10>3.0.CO;2-P","article-title":"Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson\u2019s disease and progressive supranuclear palsy","volume":"46","author":"Shinotoh","year":"1999","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B223","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B224","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.parkreldis.2014.06.004","article-title":"Parkinsonian syndrome in familial frontotemporal dementia","volume":"20","author":"Siuda","year":"2014","journal-title":"Park Relat Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B225","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0197-4580(98)00086-4","article-title":"Decreased monoamine metabolites in frontotemporal dementia and Alzheimer\u2019s disease","volume":"19","author":"Sjogren","year":"1998","journal-title":"Neurobiol Aging"},{"key":"key\n\t\t\t\t20180625113834_awx327-B226","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","article-title":"CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival","volume":"83","author":"Skillback","year":"2014","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B227","doi-asserted-by":"crossref","first-page":"D1054","DOI":"10.1093\/nar\/gkv1037","article-title":"The IUPHAR\/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands","volume":"44","author":"Southan","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"key\n\t\t\t\t20180625113834_awx327-B228","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/archneur.1991.00530200032014","article-title":"Altered serotonergic and cholinergic synaptic markers in Pick\u2019s disease","volume":"48","author":"Sparks","year":"1991","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B229","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/archneur.1991.00530190064017","article-title":"Alterations in brain monoamine oxidase activity in aging, Alzheimer\u2019s Disease, and Pick\u2019s Disease","volume":"48","author":"Sparks","year":"1991","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B230","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40263-016-0347-2","article-title":"A review of treatment options for progressive supranuclear palsy","volume":"30","author":"Stamelou","year":"2016","journal-title":"CNS Drugs"},{"key":"key\n\t\t\t\t20180625113834_awx327-B231","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/mds.22533","article-title":"Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy","volume":"24","author":"Stamelou","year":"2009","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B232","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1212\/WNL.58.7.1013","article-title":"Cholinergic vesicular transporters in progressive supranuclear palsy","volume":"58","author":"Suzuki","year":"2002","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B233","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cortex.2016.07.004","article-title":"Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia","volume":"83","author":"Teipel","year":"2016","journal-title":"Cortex"},{"key":"key\n\t\t\t\t20180625113834_awx327-B234","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11940-014-0319-0","article-title":"Treatment of frontotemporal dementia","volume":"16","author":"Tsai","year":"2014","journal-title":"Curr Treat Options Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B235","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1212\/WNL.43.10.1918","article-title":"Levodopa therapy and survival in idiopathic Parkinson\u2019s disease: Olmsted County project","volume":"43","author":"Uitti","year":"1993","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180625113834_awx327-B236","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jalz.2012.06.010","article-title":"Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia","volume":"9","author":"Vermeiren","year":"2013","journal-title":"Alzheimers Dement"},{"key":"key\n\t\t\t\t20180625113834_awx327-B237","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3233\/JAD-160320","article-title":"Brain serotonergic and noradrenergic deficiencies in behavioral variant frontotemporal dementia compared to early-onset Alzheimer\u2019s disease","volume":"53","author":"Vermeiren","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"key\n\t\t\t\t20180625113834_awx327-B238","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ana.22237","article-title":"Noradrenergic enhancement improves motor network connectivity in stroke patients","volume":"69","author":"Wang","year":"2011","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B239","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.neuron.2012.12.032","article-title":"NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex","volume":"77","author":"Wang","year":"2013","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20180625113834_awx327-B240","doi-asserted-by":"crossref","first-page":"16482","DOI":"10.1523\/JNEUROSCI.3418-14.2014","article-title":"Tau-Mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia","volume":"34","author":"Warmus","year":"2014","journal-title":"J Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B241","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/mds.21573","article-title":"Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy","volume":"22","author":"Warren","year":"2007","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B242","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/jnnp.2006.099937","article-title":"The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases","volume":"78","author":"Warren","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B243","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/brain\/awh391","article-title":"Cholinergic systems in progressive supranuclear palsy","volume":"128","author":"Warren","year":"2005","journal-title":"Brain"},{"key":"key\n\t\t\t\t20180625113834_awx327-B244","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archneur.1991.00530140061018","article-title":"The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography","volume":"48","author":"Weinberger","year":"1991","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B245","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1001\/archneur.62.9.1402","article-title":"Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia","volume":"62","author":"Whitwell","year":"2005","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B246","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1503\/jpn.100021","article-title":"Gamma oscillations and schizophrenia","volume":"35","author":"Williams","year":"2010","journal-title":"J Psychiatry Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B247","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrn1406","article-title":"Dopamine, learning and motivation","volume":"5","author":"Wise","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B248","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0022-510X(83)90200-9","article-title":"A post-mortem comparison of the cortical cholinergic system in Alzheimer\u2019s disease and Pick\u2019s disease","volume":"62","author":"Wood","year":"1983","journal-title":"J Neurol Sci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B249","first-page":"S87","article-title":"PROSPECT: a UK-based longitudinal observational study of PSP, CBD, MSA and atypical Parkinsonism syndromes [abstract]","volume":"31","author":"Woodside","year":"2016","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t20180625113834_awx327-B250","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s004010000293","article-title":"Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method","volume":"101","author":"Yang","year":"2001","journal-title":"Acta Neuropathol"},{"key":"key\n\t\t\t\t20180625113834_awx327-B251","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0022-510X(80)90205-1","article-title":"Neurochemical observations in a case or Pick\u2019s disease","volume":"48","author":"Yates","year":"1980","journal-title":"J Neurol Sci"},{"key":"key\n\t\t\t\t20180625113834_awx327-B252","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.biopsych.2014.01.024","article-title":"Improving response inhibition in Parkinson\u2019s disease with atomoxetine","volume":"77","author":"Ye","year":"2015","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20180625113834_awx327-B253","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nicl.2015.07.017","article-title":"The 5-HTTLPR variant in the serotonin transporter gene modifies degeneration of brain regions important for emotion in behavioral variant frontotemporal dementia Serotonin transporter in bvFTD","volume":"9","author":"Yokoyama","year":"2015","journal-title":"Neuroimage Clin"},{"key":"key\n\t\t\t\t20180625113834_awx327-B254","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/brain\/awv331","article-title":"Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson\u2019s disease","volume":"139","author":"Zhang","year":"2016","journal-title":"Brain"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/141\/5\/1263\/25083092\/awx327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T21:34:02Z","timestamp":1719610442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/141\/5\/1263\/4823510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,24]]},"references-count":255,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,1,24]]},"published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awx327","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,5]]},"published":{"date-parts":[[2018,1,24]]}}}